PROMISS Diagnostics, Inc., a Milwaukee-based company developing an early-detection ovarian cancer test, has raised $400,000 in a seed round of funding, the company announced Friday.
The funding round was led by the Wisconsin Alumni Research Foundation with additional investments from Cream City Venture Capital, Northwestern Mutual’s $5 million venture fund.
PROMISS Diagnostics is a venture-stage biotech company that develops bio-analytical solutions to assist physicians in improving women’s health outcomes. PROMISS Diagnostics president and chief executive office Jalal Sulaiman founded the company in 2017.
Its first-generation multi-analyte blood test (named PROMISS, for “Predicting Risk of Ovarian Malignancy in Serum Samples”) distinguishes malignant from benign ovarian masses.
;
